For instance, two randomised Phase III trials suggest that afatinib failed to prolong patient life in the whole tested population of EGFR-mutant advanced lung cancer [47], however, afatinib significantly extended survival by 3 months to a specific EGFR-mutated subgroup compared to chemotherapy [48]. This evidence concerns the gene EGFR and lung carcinoma.